Intramol0.5%

Intramol is a non-selective beta-adrenergic blocking agent used both topically (as eye drops) and, in some markets, orally (as tablets), depending on the indication.

Established / FDA-approved uses

• Ophthalmic: reduction of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma, used alone or in combination with other IOP-lowering agents.
• Oral (where marketed): management of hypertension, reduction of cardiovascular mortality and reinfarction risk in clinically stable patients after acute myocardial infarction, and prophylaxis of migraine headache.

Adjunct / combination use

• In glaucoma that is inadequately controlled on a single agent, ophthalmic Intramol is frequently added to prostaglandin analogues, carbonic anhydrase inhibitors, or alpha-agonists as combination therapy.
• Oral Intramol is not typically used as monotherapy for angina but may be used as part of a broader antianginal regimen.

Off-label use

• Topical (compounded gel) Intramol is used off-label by some specialists for selected superficial infantile hemangiomas, under close medical supervision; this is not an FDA-approved indication and requires specialist guidance.

In Bangladesh, Intramol is primarily marketed and used as an ophthalmic (eye drop) preparation for glaucoma and ocular hypertension.

Each mL of Timolol Maleate ophthalmic solution typically contains Timolol Maleate equivalent to 0.25% or 0.5% timolol base, formulated as eye drops or a gel-forming ophthalmic solution. Where marketed orally, Timolol Maleate tablets are typically available in strengths equivalent to 5 mg, 10 mg, or 20 mg of timolol base.

Intramol is a non-selective beta-adrenergic (beta-blocker) agent that blocks both beta-1 and beta-2 adrenergic receptors. It is available as an ophthalmic solution/gel-forming solution used to lower elevated intraocular pressure in glaucoma and ocular hypertension, and in some countries as oral tablets used for hypertension, angina, migraine prophylaxis, and secondary prevention after myocardial infarction.

Intramol does not cure glaucoma but helps control intraocular pressure to reduce the risk of optic nerve damage and vision loss; regular use and follow-up eye examinations are important.

Intramol belongs to the non-selective beta-adrenergic blocking agents (beta-blockers). Depending on route, it is classified as an ocular hypotensive/anti-glaucoma agent (ophthalmic use) or as an antihypertensive, antianginal, and migraine-prophylactic agent (oral use).

Mechanism

Timolol Maleate non-selectively blocks beta-1 (cardiac) and beta-2 (bronchial, vascular) adrenergic receptors, without significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

Ophthalmic use

Applied topically, Timolol Maleate reduces elevated intraocular pressure by decreasing aqueous humor production, with little or no effect on pupil size or accommodation. The onset of action is within about 20 minutes, with maximal effect typically seen within 1-2 hours and a duration of action lasting up to 24 hours, allowing once- or twice-daily dosing.

Oral use

Systemically, Timolol Maleate reduces heart rate, myocardial contractility, cardiac output, and renin release, lowering blood pressure and myocardial oxygen demand. Even topical ophthalmic Timolol Maleate is absorbed systemically via the nasolacrimal duct and can produce measurable systemic beta-blockade.

Pharmacokinetics

After ophthalmic administration, peak plasma concentrations occur within 1-2 hours. After oral administration, Timolol Maleate is well absorbed, undergoes some hepatic first-pass metabolism, and is eliminated mainly via the kidneys, with an elimination half-life of approximately 4 hours.

Eye drops

• Wash hands before use; avoid letting the dropper tip touch the eye, eyelid, or any surface, to prevent contamination.
• Tilt the head back, pull down the lower eyelid to form a small pocket, and instill one drop.
• Apply gentle pressure to the inner corner of the eye (punctal occlusion) or close the eyelid for 1-2 minutes after instillation to reduce systemic absorption.
• If using more than one topical eye medicine, wait at least 5-10 minutes between different products.
• Remove soft contact lenses before instillation and wait at least 15 minutes before reinserting them, as some formulations contain preservatives that can be absorbed by soft lenses.

Oral tablets

• Take at the same time(s) each day, with or without food, as directed by the physician.
• Swallow tablets whole with water; do not crush or split extended-release products unless advised.
• Do not stop taking oral Intramol suddenly without medical advice.

Intramol can interact with several other medicines, mainly related to its beta-blocking activity. Clinically significant interactions include:

• Other beta-blockers (oral or ophthalmic): concurrent use with Intramol may cause additive effects on intraocular pressure and/or systemic beta-blockade; avoid combining two beta-blockers unless specifically directed.
• Calcium channel blockers (e.g., verapamil, diltiazem): increased risk of atrioventricular conduction disturbances, left ventricular failure, and hypotension when combined with Intramol, particularly with intravenous calcium channel blockers.
• Clonidine: beta-blockers including Intramol may worsen the rebound hypertension that can occur when clonidine is withdrawn; if both are used, Intramol should be discontinued several days before clonidine is tapered.
• Digoxin and other agents slowing AV conduction: additive bradycardia and AV conduction delay.
• Insulin and oral hypoglycemic agents: Intramol can mask the tachycardia associated with hypoglycemia, delaying recognition of low blood sugar; blood glucose should be monitored closely.
• Epinephrine (adrenaline): in patients on Intramol, the response to epinephrine used for severe allergic reactions/anaphylaxis may be blunted, and larger doses of epinephrine may be required.
• CYP2D6 inhibitors (e.g., quinidine): can increase systemic levels and beta-blocking effect of Intramol, including from ophthalmic use.
• Catecholamine-depleting drugs (e.g., reserpine): additive effect, with risk of hypotension and marked bradycardia.

Always inform the physician or pharmacist about all other medicines, including other eye drops, being used with Intramol.

Ophthalmic use

• Common: transient burning or stinging on instillation, eye irritation, dryness, itching, blurred vision, conjunctival redness, and decreased corneal sensitivity.
• Less common but important: because of systemic absorption, Intramol eye drops can cause systemic beta-blocker effects such as slow heart rate (bradycardia), low blood pressure, fatigue, and bronchospasm/breathing difficulty, particularly in susceptible patients.

Oral use

• Common: fatigue, dizziness, cold hands/feet, bradycardia, and mild gastrointestinal upset.
• Less common: hypotension, bronchospasm (especially in patients with reactive airway disease), sleep disturbances, depression, and masking of hypoglycemia symptoms in patients with diabetes.

Patients should seek prompt medical attention for signs of a very slow heart rate, fainting, severe shortness of breath, or wheeze while using Intramol.

Pregnancy: There are no adequate and well-controlled studies of Intramol in pregnant women. Intramol should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under close medical supervision. Neonates of mothers treated with beta-blockers near term should be monitored for signs of beta-blockade (e.g., bradycardia, low blood sugar) after delivery.

Lactation: Intramol has been detected in human breast milk after both oral and ophthalmic administration. A decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue Intramol, taking into account the importance of the medicine to the mother and the potential for beta-blocker effects in the nursing infant.

• Cardiac disease: use with caution in patients with compensated heart failure or conduction abnormalities; Intramol can further slow heart rate and depress cardiac function.
• Respiratory disease: although applied topically, ophthalmic Intramol can be systemically absorbed and provoke bronchospasm in patients with a history of asthma or COPD; see Contraindications.
• Diabetes mellitus: Intramol can mask the warning signs (e.g., rapid heartbeat) of hypoglycemia; monitor blood glucose closely.
• Thyroid disease: abrupt withdrawal of beta-blockers may precipitate a thyroid storm in patients with thyrotoxicosis, and Intramol can mask signs of hyperthyroidism.
• Myasthenia gravis: beta-blockade with Intramol may potentiate muscle weakness.
• Major surgery/anesthesia: inform the anesthesiologist that the patient is using Intramol, as beta-blockade may affect the heart's ability to respond to stress during surgery.
• Abrupt discontinuation (oral use): do not stop oral Intramol suddenly; abrupt withdrawal has been associated with exacerbation of angina, myocardial infarction, and ventricular arrhythmias in patients with coronary artery disease. Taper the dose gradually under medical supervision.
• Anaphylaxis: patients on Intramol may have a more severe response to allergens and may not respond to the usual doses of epinephrine used to treat anaphylactic reactions.
• Administration technique (eye drops): use punctal occlusion or eyelid closure for 1-2 minutes after each dose to reduce systemic absorption and side effects; avoid contaminating the dropper tip.
• Driving/operating machinery: Intramol may occasionally cause blurred vision, fatigue, or dizziness; use caution until the effect on the individual is known.

Overdose with Intramol (particularly oral, but also ophthalmic if a large amount is ingested, such as by a child) can cause symptoms of excessive beta-blockade, including a very slow heart rate (bradycardia), low blood pressure, severe fatigue, dizziness, fainting, difficulty breathing or bronchospasm, and in severe cases, heart failure, cardiac arrest, or seizures.

Suspected overdose with Intramol is a medical emergency. Seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to manage a suspected overdose at home; treatment is supportive and must be provided under medical supervision in a hospital setting.

Store Intramol eye drops/tablets at controlled room temperature, generally 15°C to 25°C (59°F to 77°F), protected from light. Keep the bottle tightly closed when not in use, do not freeze, and discard any remaining ophthalmic solution after the manufacturer's recommended in-use period. Keep out of reach of children.

• Renal impairment: Intramol is largely eliminated renally after oral use; dose adjustment or careful monitoring may be needed in significant renal impairment, and Intramol is not readily removed by dialysis.
• Hepatic impairment: use with caution; specific dose adjustment data are limited, so close monitoring is advised.
• Elderly: no specific dose adjustment is established, but elderly patients may be more sensitive to blood-pressure-lowering and heart-rate-lowering effects; monitor closely.
• Pediatric use: see Pediatric Uses below.
• Pregnancy and lactation: see Pregnancy and Lactation above.

For glaucoma and ocular hypertension, Intramol is typically used long-term (often lifelong) to control intraocular pressure, with periodic eye examinations to reassess IOP, optic nerve status, and visual fields. For hypertension and post-MI cardioprotection, oral Intramol is generally continued long-term as directed by the physician. For migraine prophylaxis, a treatment trial of at least 2-3 months is usually needed to assess benefit, with periodic reassessment of continued need. Treatment duration should always be determined by the prescribing physician based on response and tolerability.

Non-selective beta-adrenergic blocking agent (beta-blocker); ocular hypotensive/anti-glaucoma agent (ophthalmic use); antihypertensive, antianginal, and migraine-prophylactic agent (oral use).

Timolol Maleate works by non-selectively blocking beta-1 and beta-2 adrenergic receptors. In the eye, this reduces the production of aqueous humor by the ciliary body, thereby lowering elevated intraocular pressure. Systemically (whether from oral dosing or absorption of eye drops), beta-blockade reduces heart rate, myocardial contractility, cardiac output, and renin release, which lowers blood pressure and myocardial oxygen demand.

C

Oral use: the safety and effectiveness of oral Intramol have not been established in children and adolescents; it is not approved for pediatric use by this route.

Ophthalmic use: the safety and effectiveness of ophthalmic Intramol have also not been formally established in pediatric patients, particularly infants, who may be more susceptible to systemic beta-blocker effects such as bradycardia, low blood sugar, and apnea. Some specialists use topical Intramol off-label under close supervision for selected conditions such as infantile hemangiomas; this should only be done under the direct guidance of a specialist physician, with monitoring for systemic side effects.